From March 13th – 17th, 2017, US-FDA carried out a cGMP inspection at Lianhetech’s Jiangkou site.

The Establishment Inspection Report was received on June 8th, 2017, stating that with zero observation, Jiangkou site successfully passed the inspection.

This was the first time Lianhetech received an US FDA cGMP inspection after China FDA’s first cGMP inspection in 2005 and EMA’s first cGMP inspection in 2007.

This successful inspection is testimony to Lianhetech’s quality & compliance culture and strong commitment to our pharmaceutical customers strengthening our pharmaceutical CDMO business development further.